Abstract：Objective To summarize the research progress of stem cells and tissue engineering for surgical reconstruction of congenital heart disease.Methods Literature data of congenital heart disease, stem cells, tissue engineering, surgical reconstruction from Wanfang database and PubMed from Jan 2005 to Dec 2014 were collected and analyzed.Results Adult stem cells, especially bone marrow mesenchymal stem cells were successfully used in tissue engineering of myocardial tissue or vascular grafts for reconstruction of congenital heart disease. Excellent initial results were achieved in large animal models (dog and sheep). Clinical application of engineered vascular autografts in surgical reconstruction of single ventricle malformation with good clinical results had been reported. Embryonic stem cells (ESCs) have high proliferation potential and can differentiate into functional cardiomyocytes and endothelial cells. The myocardial tissue engineered using ESCs have characters of neonatal myocardial tissue. Induced pluripotent stem cells, like ESCs, can differentiate into cell of 3 lineages, but without ethical problem, will play an important role in myocardial and vascular tissue engineering.Conclusions The results of stem cells and tissue engineering in surgical reconstruction of congenital heart disease were encouraging, and will play a more important role in this field with the research progress of stem cells.
武开宏,孙剑,莫绪明. 干细胞组织工程构建先天性心脏病重建材料的研究进展[J]. 中华解剖与临床杂志, 2015, 20(4): 365-367.
Wu Kaihong, Sun Jian, Mo Xuming.. Application of stem cells and tissue engineering for reconstruction of congenital heart disease. Chinese Journal of Anatomy and Clinics, 2015, 20(4): 365-367.
Ye L, Zimmermann WH, Garry DJ, et al. Patching the heart: cardiac repair from within and outside[J]. Circ Res, 2013, 113(7): 922-932.
[2]
Gist KM, Mitchell MB, Jaggers J, et al. Assessment of the relationship between contegra conduit size and early valvar insufficiency[J]. Ann Thorac Surg, 2012, 93(3): 856-861.
[3]
Buikema JW, Van Der Meer P, Sluijter JP, et al. Concise review: Engineering myocardial tissue: the convergence of stem cells biology and tissue engineering technology[J]. Stem Cells, 2013, 31(12): 2587-2598.
[4]
Wu KH, Mo XM, Han ZC, et al. Stem cell engraftment and survival in the ischemic heart[J]. Ann Thorac Surg, 2011, 92(5): 1917-1925.
[5]
Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors[J]. Cell, 2006, 126(4): 663-676.
[6]
Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors[J]. Cell, 2007, 131(5): 861-872.
Rabiee F, Forouzanfar M, Ghazvini Zadegan F, et al. Induced expression of Fndc5 significantly increased cardiomyocyte differentiation rate of mouse embryonic stem cells[J]. Gene, 2014, 551(2): 127-137.
[11]
Kurtovic S, Ng TT, Gupta A, et al. Leptin enhances endothelial cell differentiation and angiogenesis in murine embryonic stem cells[J]. Microvasc Res, 2015, 97: 65-74.
[12]
Kado M, Lee JK, Hidaka K, et al. Paracrine factors of vascular endothelial cells facilitate cardiomyocyte differentiation of mouse embryonic stem cells[J]. Biochem Biophys Res Commun, 2008, 377(2): 413-418.
[13]
Baker M. Court lifts cloud over embryonic stem cells[J]. Nature, 2013, 493(7432): 282.
[14]
Hodonsky C, Wu K, Mundada L, et al. Generation of human cardiomyocytes for cardiac regenerative therapies: differentiation and direct reprogramming[J]. Curr Pharm Des, 2014, 20(12): 2012-2022.
[15]
Savla JJ, Nelson BC, Perry CN, et al. Induced pluripotent stem cells for the study of cardiovascular disease[J]. J Am Coll Cardiol, 2014, 64(5): 512-519.
Caspi O, Lesman A, Basevitch Y, et al. Tissue engineering of vascularized cardiac muscle from human embryonic stem cells[J]. Circ Res, 2007, 100(2): 263-272.
[18]
Guo XM, Zhao YS, Chang HX, et al. Creation of engineered cardiac tissue in vitro from mouse embryonic stem cells[J]. Circulation, 2006, 113(18): 2229-2237.
[19]
Wu KH, Mo XM, Liu YL. Cell sheet engineering for the injured heart[J]. Med Hypotheses, 2008, 71(5): 700-702.
[20]
Castells-Sala C, Semino CE. Biomaterials for stem cell culture and seeding for the generation and delivery of cardiac myocytes[J]. Curr Opin Organ Transplant, 2012, 17(6): 681-687.
[21]
Wang B, Williams LN, de Jongh Curry AL, et al. Preparation of acellular myocardial scaffolds with well-preserved cardiomyocyte lacunae, and method for applying mechanical and electrical simulation to tissue construct[J]. Methods Mol Biol, 2014, 1181: 189-202.
[22]
Iwasaki K, Kojima K, Kodama S, et al. Bioengineered three-layered robust and elastic artery using hemodynamically-equivalent pulsatile bioreactor[J]. Circulation, 2008, 118(14 Suppl): S52-57.
[23]
Hulsmann J, Aubin H, Kranz A, et al. A novel customizable modular bioreactor system for whole-heart cultivation under controlled 3D biomechanical stimulation[J]. J Artif Organs, 2013, 16(3): 294-304.
[24]
Cittadini A, Monti MG, Petrillo V, et al. Complementary therapeutic effects of dual delivery of insulin-like growth factor-1 and vascular endothelial growth factor by gelatin microspheres in experimental heart failure[J]. Eur J Heart Fail, 2011, 13(12): 1264-1274.
[25]
Matsumura G, Miyagawa-Tomita S, Shin′oka T, et al. First evidence that bone marrow cells contribute to the construction of tissue-engineered vascular autografts in vivo[J]. Circulation, 2003, 108(14): 1729-1734.
[26]
Mettler BA, Sales VL, Stucken CL, et al. Stem cell-derived, tissue-engineered pulmonary artery augmentation patches in vivo[J]. Ann Thorac Surg, 2008, 86(1): 132-140.
[27]
Gottlieb D, Kunal T, Emani S, et al. In vivo monitoring of function of autologous engineered pulmonary valve[J]. J Thorac Cardiovasc Surg, 2010, 139(3): 723-731.
[28]
Mihic A, Li J, Miyagi Y, et al. The effect of cyclic stretch on maturation and 3D tissue formation of human embryonic stem cell-derived cardiomyocytes[J]. Biomaterials, 2014, 35(9): 2798-2808.
[29]
Kawamura M, Miyagawa S, Miki K, et al. Feasibility, safety, and therapeutic efficacy of human induced pluripotent stem cell-derived cardiomyocyte sheets in a porcine ischemic cardiomyopathy model[J]. Circulation, 2012, 126(11 Suppl 1): S29-37.
[30]
Shin′oka T, Matsumura G, Hibino N, et al. Midterm clinical result of tissue-engineered vascular autografts seeded with autologous bone marrow cells[J]. J Thorac Cardiovasc Surg, 2005, 129(6): 1330-1338.
[31]
Hibino N, McGillicuddy E, Matsumura G, et al. Late-term results of tissue-engineered vascular grafts in humans[J]. J Thorac Cardiovasc Surg, 2010, 139(2): 431-436.
[32]
Di Bernardini E, Campagnolo P, Margariti A, et al. Endothelial lineage differentiation from induced pluripotent stem cells is regulated by microRNA-21 and transforming growth factor β2 (TGF-β2) pathways[J]. J Biol Chem, 2014, 289(6): 3383-3393.
2015, Vol. 20 
